Approval · Notice of Compliance 18987 · 2017

REXULTI: Notice of Compliance 18987

Issued February 16, 2017

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 18987
Date: February 16, 2017
Company: Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, Japan
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)

Products in this notice

Brand	DIN	Status today
REXULTI	02461749	Marketed
REXULTI	02461757	Marketed
REXULTI	02461765	Marketed
REXULTI	02461773	Marketed
REXULTI	02461781	Marketed
REXULTI	02461803	Marketed

Medicinal ingredients

BREXPIPRAZOLE 0.25 MG per TAB
BREXPIPRAZOLE 0.5 MG per TAB
BREXPIPRAZOLE 1 MG per TAB
BREXPIPRAZOLE 2 MG per TAB
BREXPIPRAZOLE 3 MG per TAB
BREXPIPRAZOLE 4 MG per TAB